CARDIX THERAPEUTICS
A Patent Drug for Improving
Cardiac Function
Cardiovascular disease is the leading cause of death in the United States and globally. The improving cardiac function and treatment of chronic bradycardia (Heart Rate ≤ 60 beats per minute) remain an essential unsolved issue. With no regulatory-approved this type of drug for treatment, a pacemaker is used surgically placed into a patient's heart. With the limitation of pacemakers, some patients may face high risk. Notably, in some situations, such as in Space, when the element of gravity is replaced with weightlessness, a human heart shrinks, and the heart rate and cardiac output are lower in Space than on Earth observed in astronauts.
CARDIX Therapeutics is developing a new patent drug to improve cardiac function by increasing heart rate and cardiac output. The patent drug provides an alternative option to a pacemaker for treating chronic bradycardia. With a non-invasive methodology and non-electromagnetic interferences, it is promising to be suitable for astronauts/spacemen to protect or ameliorate their cardiac function in Space.
